MedTrace Logo

Skin Protectant Properties of Omeza Collagen Matrix on Damaged Skin

NCT04512274 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2022-09-30

No results posted yet for this study

Summary

Single-blind within subject comparison study conducted to investigate the skin protectant properties of Omeza Collagen Matrix on damaged skin

Conditions

  • Transepidermal Water Loss
  • Erythema

Interventions

DEVICE

Test Article

Omeza Collagen Matrix

Sponsors & Collaborators

  • Omeza, LLC

    lead INDUSTRY

Principal Investigators

  • Barrie Drewitt · PCR Corp

  • Andrew King · PCR Corp

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2020-06-05
Completion
2020-06-05
FDA Device
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04512274 on ClinicalTrials.gov